Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on oncology that reached public markets through a merger with Panacea Acquisition Corp. II, a blank-check vehicle sponsored by Panacea Acquisition Management. The SPAC completed its initial public offering in 2021, with the business combination closing in early 2022. Currently listed on the NYSE, Nuvation Bio is advancing a pipeline of novel cancer therapeutics targeting multiple tumor types. The company submitted an 8-K to the Securities and Exchange Commission on March 25, 2024, under accession number 0001193125-24-075908. For full filing history, SPAC transaction data, and analytics on NUVB, sign up for SpacDesk at spacdesk.com.